Characteristics of Oncology Clinical Trials

Bradford R. Hirsch, Robert M. Califf, Steven K. Cheng, +6

JAMA Internal Medicine

The Prevalence and Economic Impact of Low-Enrolling Clinical Studies at an Academic Medical Center

Darlene Kitterman, Steven K. Cheng, David M. Dilts, +1

Academic Medicine

A Sense of Urgency: Evaluating the Link between Clinical Trial Development Time and the Accrual Performance of Cancer Therapy Evaluation Program (NCI-CTEP) Sponsored Studies

Steven K. Cheng, Mary S. Dietrich, David M. Dilts

Clinical Cancer Research

A randomized controlled trial of colchicine plus ursodiol versus methotrexate plus ursodiol in primary biliary cirrhosis: Ten-year results

Marshall M. Kaplan, Steven K. Cheng, Lori Lyn Price, +1

Hepatology

Processes to Activate Phase III Clinical Trials in a Cooperative Oncology Group: The Case of Cancer and Leukemia Group B

David M. Dilts, Alan B. Sandler, Matthew J. Baker, +11

Journal of Clinical Oncology

Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program

David M. Dilts, Alan B. Sandler, Steven K. Cheng, +7

Journal of Clinical Oncology

Phase III Clinical Trial Development: A Process of Chutes and Ladders

David M. Dilts, Steven K. Cheng, Joshua S. Crites, +2

Clinical Cancer Research

Development of Clinical Trials in a Cooperative Group Setting: The Eastern Cooperative Oncology Group

David M. Dilts, Alan Sandler, Steven K. Cheng, +7

Clinical Cancer Research

Predicting Accrual Achievement: Monitoring Accrual Milestones of NCI-CTEP–Sponsored Clinical Trials

Steven K. Cheng, Mary S. Dietrich, David M. Dilts

Clinical Cancer Research